| Latest | F'cast | |
|---|---|---|
| Div Yield | 1.7% | |
| Div Cover | 2.1 | |
| Op Mrgn | 23.4% | |
| ROCE | 59.5% |
| Latest | F'cast | |
|---|---|---|
| P/E | 28.2 | |
| PEG | 0.6 | |
| Pr/Revenue | 4.0 | |
| Pr/Book | 4.8 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 8.6% | |
| PBT | 42.7% | |
| EPS | 45.4% | |
| DPS | 3.2% |
| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-21 | 37,417.00 | (265.00) | 8.00¢ | 1,440.9 | n/a | -97% | 287.00¢ | 2.5% |
| 31-Dec-22 | 44,351.00 | 2,501.00 | 212.00¢ | 70.6 | 0.0 | +2,550% | 290.00¢ | 1.9% |
| 31-Dec-23 | 45,811.00 | 6,899.00 | 726.00¢ | 19.4 | 0.1 | +242% | 290.00¢ | 2.1% |
| 31-Dec-24 | 54,073.00 | 8,691.00 | 454.00¢ | 30.7 | n/a | -38% | 310.00¢ | 2.2% |
| 31-Dec-25 | 58,739.00 | 12,402.00 | 660.00¢ | 27.8 | 0.6 | +45% | 320.00¢ | 1.7% |
| Imfinzi approved in EU for early gastric cancer | 16-Mar-2026 | 07:00 | RNS |
| Notice of AGM | 10-Mar-2026 | 11:00 | RNS |
| Director/PDMR Shareholding | 22-Dec-2025 | 11:00 | RNS |
| Director/PDMR Shareholding | 22-Dec-2025 | ShareCast |
| Enhertu granted BTD for post-neoadjuvant early BC | 22-Dec-2025 | ShareCast |
| Update on LATIFY Phase III trial of ceralasertib | 22-Dec-2025 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 12,760.00p |
| Change Today | 0.70p |
| % Change | 0.55 % |
| 52 Week High | 15,286.00 |
| 52 Week Low | 10,745.00 |
| Volume | 334,086 |
| Shares Issued | 1,264.16m |
| Market Cap | £161,307m |
| Time | Volume / Share Price |
| 16:29 | 31 @ 12,760.00p |
| 16:29 | 156 @ 12,761.00p |
| 16:29 | 50 @ 12,756.00p |
| 16:29 | 50 @ 12,756.00p |
| 16:29 | 25 @ 12,755.00p |
You are here: research